[go: up one dir, main page]

WO2010022055A3 - 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders - Google Patents

1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders Download PDF

Info

Publication number
WO2010022055A3
WO2010022055A3 PCT/US2009/054169 US2009054169W WO2010022055A3 WO 2010022055 A3 WO2010022055 A3 WO 2010022055A3 US 2009054169 W US2009054169 W US 2009054169W WO 2010022055 A3 WO2010022055 A3 WO 2010022055A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
chronic pain
pain disorders
derivatives useful
ine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/054169
Other languages
French (fr)
Other versions
WO2010022055A2 (en
Inventor
John L. Buchanan
Howard Bregman
Nagasree Chakka
Erin F. Dimauro
Bingfan Du
Hanh Nho Nguyen
Xiao Mei Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of WO2010022055A2 publication Critical patent/WO2010022055A2/en
Publication of WO2010022055A3 publication Critical patent/WO2010022055A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides compounds that are inhibitors of voltage-gated sodium channel (Nav), in particular Nav 1.7 and are therefore useful for the treatment of diseases 5 treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
PCT/US2009/054169 2008-08-20 2009-08-18 Inhibitors of voltage-gated sodium channels Ceased WO2010022055A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18950108P 2008-08-20 2008-08-20
US61/189,501 2008-08-20
US19601208P 2008-10-14 2008-10-14
US61/196,012 2008-10-14

Publications (2)

Publication Number Publication Date
WO2010022055A2 WO2010022055A2 (en) 2010-02-25
WO2010022055A3 true WO2010022055A3 (en) 2010-06-17

Family

ID=41707632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/054169 Ceased WO2010022055A2 (en) 2008-08-20 2009-08-18 Inhibitors of voltage-gated sodium channels

Country Status (1)

Country Link
WO (1) WO2010022055A2 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103196A1 (en) * 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
US9273027B2 (en) * 2010-02-24 2016-03-01 Research Triangle Institute Arylpiperazine opioid receptor antagonists
US8871996B2 (en) 2010-06-09 2014-10-28 Regeneron Pharmaceuticals, Inc. Mice expressing human voltage-gated sodium channels
US8486647B2 (en) 2010-06-09 2013-07-16 Regeneron Pharmaceuticals, Inc. Neuropeptide release assay for sodium channels
CN102344407A (en) * 2010-08-03 2012-02-08 艾琪康医药科技（上海）有限公司 3-droperidol derivative and preparation method thereof
RS54544B1 (en) * 2010-09-13 2016-06-30 Novartis Ag TRIAZINE-OXADIAZOLES
EP2681193B1 (en) 2011-03-02 2016-01-06 Lead Discovery Center GmbH Pharmaceutically active disubstituted pyridine derivatives
US9226929B2 (en) 2011-03-02 2016-01-05 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
CN102285969B (en) * 2011-06-28 2013-06-19 山东大学 N-1-substituted piperidin-4-arylamine derivatives and preparation method and use thereof
JP6014155B2 (en) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Biaryl ether sulfonamides and their use as therapeutic agents
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
KR101719893B1 (en) 2012-05-22 2017-03-24 제넨테크, 인크. N-substituted benzamides and their use in the treatment of pain
JP6309519B2 (en) 2012-07-06 2018-04-11 ジェネンテック， インコーポレイテッド N-substituted benzamide and method of using the same
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
US9040712B2 (en) * 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
US9187468B2 (en) 2013-02-13 2015-11-17 Novartis Ag Topical ocular analgesic agents
WO2014153037A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
GB2516303A (en) * 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
CA2922567A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
WO2015050212A1 (en) * 2013-10-02 2015-04-09 日産化学工業株式会社 T-type calcium channel blocker
ES2683127T3 (en) 2013-10-17 2018-09-25 Blueprint Medicines Corporation Useful compositions for treating disorders related to KIT
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
AU2014356967A1 (en) 2013-11-27 2016-07-07 Genentech, Inc. Substituted benzamides and methods of use thereof
JP6556154B2 (en) 2014-02-12 2019-08-07 パーデュー、ファーマ、リミテッド、パートナーシップ Isoquinoline derivatives and uses thereof
TR201809388T4 (en) * 2014-03-17 2018-07-23 Pfizer Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related diseases.
CN104016977B (en) * 2014-06-13 2016-06-22 山东大学 A kind of replacement thiadiazine diketone derivative and preparation method thereof and application
JP2017525677A (en) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド Therapeutic compounds and methods of use thereof
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
MA42118A (en) 2015-05-22 2018-03-28 Genentech Inc BENZAMIDES SUBSTITUTED AND THEIR METHODS OF USE
MX2018001032A (en) 2015-07-24 2018-11-09 Blueprint Medicines Corp Compounds useful for treating disorders related to kit and pdgfr.
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
MX386501B (en) 2015-09-28 2025-03-19 Genentech Inc Therapeutic compounds and methods of use thereof
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
CN105837525B (en) * 2016-03-25 2019-05-28 浙江工业大学 2, 4-diamine-1, 3,5-triazine compound and preparation method and application thereof
US10766858B2 (en) 2016-03-30 2020-09-08 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2019532077A (en) 2016-10-17 2019-11-07 ジェネンテック， インコーポレイテッド Therapeutic compounds and methods of use thereof
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
FI3541784T3 (en) 2016-11-18 2023-10-02 Integrative Res Laboratories Sweden Ab Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
AU2017374860B2 (en) 2016-12-16 2021-09-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
AU2018205275B2 (en) 2017-01-06 2024-05-02 Janssen Pharmaceutica Nv Methods for the treatment of neurological disorders
CN110546148A (en) 2017-03-24 2019-12-06 基因泰克公司 4-Piperidin-N-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
CN106995380B (en) * 2017-03-31 2018-12-28 九江善水科技股份有限公司 A kind of synthetic method of 2- Amino-4-nitrophenol
WO2019018795A1 (en) * 2017-07-20 2019-01-24 Yumanity Therapeutics Compounds and uses thereof
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
AR114263A1 (en) 2018-02-26 2020-08-12 Genentech Inc THERAPEUTIC COMPOUNDS AND METHODS TO USE THEM
AU2019238326B2 (en) 2018-03-23 2025-03-06 Janssen Pharmaceutica Nv Compounds and uses thereof
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
EP3784234A1 (en) 2018-04-25 2021-03-03 Yumanity Therapeutics, Inc. Compounds and uses thereof
TW202003490A (en) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 Therapeutic compounds and methods of use thereof
KR20220007845A (en) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. Compounds and uses thereof
LT3856341T (en) 2019-04-12 2023-12-27 Blueprint Medicines Corporation (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYROLO[2,1-F] [1,2,4 [TRIAZIN-4-IL)PIPERAZINYL)-PYRIMIDIN-5-IL)ETHAN-1-AMINO CRYSTAL FORM AND MANUFACTURING METHODS
AU2020272743B2 (en) 2019-04-12 2025-10-16 Blueprint Medicines Corporation Pyrrolotriazine derivatives for treating KIT- and PDGFRa-mediated diseases
EA202192047A1 (en) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS
CN111057021B (en) * 2019-12-11 2023-05-23 中国药科大学 s-triazine compound and its preparation method and use
NZ788624A (en) * 2019-12-23 2025-08-29 Lg Chemical Ltd Novel amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof
JP7451017B2 (en) * 2019-12-23 2024-03-18 エルジー・ケム・リミテッド Novel amide derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof
WO2023132208A1 (en) * 2022-01-07 2023-07-13 国立大学法人大阪大学 Pharmaceutical composition for preventing and/or treating heart failure
US20250177392A1 (en) * 2022-02-24 2025-06-05 Microbiotix, Inc. Broad spectrum inhibitors of cytomegalovirus
CN116178465A (en) * 2023-03-06 2023-05-30 中国科学院成都生物研究所 Four-membered ring-containing polyphenol compound and application thereof
WO2025008504A1 (en) 2023-07-06 2025-01-09 Integrative Research Laboratories Sweden Ab Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof
CN117384091B (en) * 2023-12-08 2024-02-20 四川大学华西第二医院 Amide derivative, synthesis method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083653A1 (en) * 2001-04-11 2002-10-24 Amgen Inc. Triazinyl acrylamide derivatives as kinase inhibitors
WO2002092576A1 (en) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083653A1 (en) * 2001-04-11 2002-10-24 Amgen Inc. Triazinyl acrylamide derivatives as kinase inhibitors
WO2002092576A1 (en) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents

Also Published As

Publication number Publication date
WO2010022055A2 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
WO2010022055A3 (en) 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders
WO2009012242A3 (en) Sodium channel inhibitors
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
IL196543A (en) Pyridazinone derivatives and pharmaceutical compositions comprising them for use in the treatment of disorders
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
WO2010017545A3 (en) Triazole compounds that modulate hsp90 activity
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2008135826A3 (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
WO2007021941A3 (en) Inhibitors of voltage-gated sodium channels
WO2008089307A3 (en) Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
MX346186B (en) Protein kinase inhibitors.
WO2008147797A3 (en) Ion channel modulators and methods of use
WO2005111039A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2009076454A3 (en) Compounds that modulate intracellular calcium
WO2008070016A3 (en) Inhibitors of akt activity
MX2009008253A (en) Kinase inhibitors.
WO2006135627A3 (en) Inhibitors of akt activity
WO2009036996A3 (en) Small molecule bradykinin b1 receptor antagonists
WO2005046603A3 (en) Pyridine compounds
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
WO2010042925A3 (en) Compositions and methods for treating alcohol use disorders, pain and other diseases

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09791616

Country of ref document: EP

Kind code of ref document: A2